PYC 2.50% 20.5¢ pyc therapeutics limited

Ann: Successful Competitive Drug Evaluation in Animals, page-19

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 11,366 Posts.
    lightbulb Created with Sketch. 1469
    This was the standout for me in yesterday's announcement...

    "The result from the retinal pigment epithelium/choroid layer of the eye demonstrates no efficacy of the ‘naked’ PS ASO at 0.8 micrograms per eye3 nor the escalated dose of 10 micrograms per eye for the PS backbone ASO whereas the CPP-PMO demonstrates substantial efficacy at the lower 0.8 microgram dose."

    If you refer to page 2 of the announcement dated 27/06/19 below, you will note, that not only are PYC are able to go through the 8 different layers of cells, but all the way down to the retinal pigment epithelium/choroid layer and then deliver the ASO cargo across the cell membrane and into this layer of cells - the RPE cells.

    https://phylogica.com/wp-content/uploads/2019/06/190627_Break-Through-Animal-Model-Results_1942259.pdf

    I wonder if PYC's peers read-outs are measuring the "retinal pigment epithelium/choroid layer", which is the deepest cellular layer of the retina (refer to diagram).

    Tony
 
watchlist Created with Sketch. Add PYC (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.